<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840203</url>
  </required_header>
  <id_info>
    <org_study_id>10336014</org_study_id>
    <nct_id>NCT00840203</nct_id>
  </id_info>
  <brief_title>Mesalamine 4 gm/60 mL Rectal Enema</brief_title>
  <official_title>A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 mL Rectal Enema Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the relative bioavailability of the test
      formulation of mesalamine suspension rectal enema with the already marketed reference
      formulation Rowasa® in healthy, adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Maximum Observed Concentration</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mesalamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rowasa®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rowasa® 4 gm/60 mL Rectal Enema</intervention_name>
    <description>1 x 4 gm/60 mL, single-dose</description>
    <arm_group_label>Rowasa®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine 4 gm/60 mL Rectal Enema</intervention_name>
    <description>1 x 4 gm/60 mL, single-dose</description>
    <arm_group_label>Mesalamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years or older, with a body mass index (BMI) of 30 or less.

          -  Good health as determined by lack of clinically significant abnormalities in health
             assessments performed at screening.

          -  Signed informed consent form, which meets all criteria of current FDA regulations.

          -  If female and of child bearing potential prepared to abstain from sexual intercourse
             or use a reliable method of contraception during the study (e.g. condom, IUD, hormonal
             contraceptives).

        Exclusion Criteria:

          -  If female pregnant, lactating, or likely to become pregnant during the study.

          -  History of allergy or sensitivity to mesalamine or other salicylic drugs (e.g.
             aspirin, sulfasalazine) or history of any drug hypersensitivity or intolerance which,
             in the opinion of the Investigator, would compromise the safety of the subject or the
             study.

          -  Colitis, hemorrhoids, anal fissures, or other disease of the anus, rectum or colon.

          -  Significant history or current evidence of chronic infections disease, system disorder
             or organ disorder.

          -  History of psychiatric disorders occuring within the last two years that required
             hospitalization or medication.

          -  Presence of a medical condition requiring regular treatment with prescription drugs
             (other than contraceptives).

          -  Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing
             enzymes within 30 days prior to dosing.

          -  Receipt of any drug as part of a research study within 30 days prior to dosing.

          -  Drug or alcohol addiction requiring treatment in the past 12 months.

          -  Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma
             within 14 days prior to dosing.

          -  Positive test for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.

          -  Positive test results for drugs of abuse at screening.

          -  Positive serum pregnancy test at screening.

          -  Unable or unwilling to tolerate multiple venipunctures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirley Ann Kennedy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novum Pharmaceutical Research Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novum Pharmaceutical Research Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <results_first_submitted>June 30, 2009</results_first_submitted>
  <results_first_submitted_qc>June 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2009</results_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mesalamine (Test) First</title>
          <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Rowasa® (Reference) First</title>
          <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesalamine (Test) First</title>
          <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Rowasa® (Reference) First</title>
          <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Rowasa®</title>
            <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1451.739" spread="718.488"/>
                    <measurement group_id="O2" value="1500.290" spread="778.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using the General Linear Model (GLM) procedure of SAS the bioequivalence of the test and reference products will be evaluated using average bioequivalence methodology for non-replicate crossover study design.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>97.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>88.6</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>AUC0-inf was not able to be estimated for all completing subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Rowasa®</title>
            <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>AUC0-inf was not able to be estimated for all completing subjects</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24458.932" spread="16649.166"/>
                    <measurement group_id="O2" value="26862.895" spread="21419.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using the General Linear Model (GLM) procedure of SAS the bioequivalence of the test and reference products will be evaluated using average bioequivalence methodology for non-replicate crossover study design.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>97.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>82.8</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Rowasa®</title>
            <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21543.597" spread="15674.400"/>
                    <measurement group_id="O2" value="22911.830" spread="15380.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using the General Linear Model (GLM) procedure of SAS the bioequivalence of the test and reference products will be evaluated using average bioequivalence methodology for non-replicate crossover study design.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>94.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>83.0</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Maximum Observed Concentration</title>
        <description>Cmax results for N-Acetylmesalamine metabolite</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Rowasa®</title>
            <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration</title>
          <description>Cmax results for N-Acetylmesalamine metabolite</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2274.652" spread="934.469"/>
                    <measurement group_id="O2" value="2284.884" spread="857.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using the General Linear Model (GLM) procedure of SAS the bioequivalence of the test and reference products will be evaluated using average bioequivalence methodology for non-replicate crossover study design.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>98.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>91.5</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>Metabolite results presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
        <description>AUC0-inf results for N-Acetylmesalamine metabolite</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>AUC0-inf was not able to be estimated for all completing subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Rowasa®</title>
            <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
          <description>AUC0-inf results for N-Acetylmesalamine metabolite</description>
          <population>AUC0-inf was not able to be estimated for all completing subjects</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46564.373" spread="29109.234"/>
                    <measurement group_id="O2" value="49692.278" spread="32182.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using the General Linear Model (GLM) procedure of SAS the bioequivalence of the test and reference products will be evaluated using average bioequivalence methodology for non-replicate crossover study design.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>97.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>86.7</ci_lower_limit>
            <ci_upper_limit>110</ci_upper_limit>
            <estimate_desc>Metabolite results presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
        <description>AUC0-t results for N-Acetylmesalamine metabolite</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamine</title>
            <description>Mesalamine 4gm/60mL Rectal Enema (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Rowasa®</title>
            <description>Rowasa® 4gm/60mL Rectal Enema (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
          <description>AUC0-t results for N-Acetylmesalamine metabolite</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40873.915" spread="25272.348"/>
                    <measurement group_id="O2" value="42644.677" spread="24335.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using the General Linear Model (GLM) procedure of SAS the bioequivalence of the test and reference products will be evaluated using average bioequivalence methodology for non-replicate crossover study design.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>95.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>86.1</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>Metabolite results presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

